Resistance to indomethacin-induced down-regulation of hepatic cytochrome P450 enzymes in the mice with non-functional Toll-like receptor 4

Journal of Hepatology

Volumn 39, Issue 3, 2003, Pages 349-356

  Masubuchi, Yasuhiro ^a   Horie, Toshiharu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

C3H HeJ mouse; Cytochrome P450; Endotoxin; Enteropathy; Indomethacin; Non steroidal anti inflammatory drug; Peptidoglycan; Toll like receptor 4

Indexed keywords

4 NITROCATECHOL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D2; CYTOCHROME P450 2D9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A11; CYTOCHROME P450 3A2; ENDOTOXIN; INDOMETACIN; LIPOPOLYSACCHARIDE; PARACETAMOL; PHENACETIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME REGULATION; GENE MUTATION; IMMUNOBLOTTING; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; MALE; MOUSE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0042830325     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00244-7     Document Type: Article

References (46)

1. Nolan JP. The role of endotoxin in liver injury. Gastroenterology 1975;69:1346-1356.
2. Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 1991;5:2652-2660.
3. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 2001;29:207-212.
4. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001;92:147-163.
5. Masubuchi Y, Masuda E, Horie T. Multiple mechanisms in indomethacin-induced impairment of hepatic cytochrome P450 enzymes in rats. Gastroenterology 2002;122:774-783.
6. Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 1969;54:237-249.
7. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641-662.
8. Wallace JL. Non-steroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:1000-1016.
9. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, et al. COX-1 and 2, intestinal integrity, and pathogenesis of non-steroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002;122:1913-1923.
10. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to non-steroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002;300:754-761.
11. Sultzer BM. Genetic control of leucocyte responses to endotoxin. Nature 1968;219:1253-1254.
12. Watson J, Kelly K, Largen M, Taylor BA. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol 1978;120:422-424.
13. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-2088.
14. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999;189:615-625.
15. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999;162:3749-3752.
16. Su GL, Klein RD, Aminlari A, Zhang HY, Steinstraesser L, Alarcon WH, et al. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 2000;31:932-936.
17. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-2378.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
19. Masubuchi Y, Takahashi C, Fujio N, Horie T, Suzuki T, Imaoka S, et al. Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats. Drug Metab Dispos 1995;23:999-1003.
20. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 1994;22:909-915.
21. Tassaneeyakul W, Veronese ME, Birkett DJ, Miners JO. High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes. J Chromatogr 1993;616:73-78.
22. Suzuki T, Fujita S, Narimatsu S, Masubuchi Y, Tachibana M, Ohta S, et al. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. FASEB J 1992;6:771-776.
23. Rajasenan RS, Riley RJ, Leeder JS. Expression and inducibility of antigens in severe combined immunodeficient mice recognized by human anti-P450 antibodies. Toxicol Appl Pharmacol 1995;135:89-99.
24. Sueyoshi T, Kobayashi R, Nishio K, Aida K, Moore R, Wada T, et al. A nuclear factor (NF2d9) that binds to the male-specific P450 (Cyp 2d-9) gene in mouse liver. Mol Cell Biol 1995;15:4158-4166.
25. Peters JM, Morishima H, Ward JM, Coakley CJ, Kimura S, Gonzalez FJ. Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. Toxicol Sci 1999;50:82-89.
26. Sewer MB, Barclay TB, Morgan ET. Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene. Mol Pharmacol 1998;54:273-279.
27. Yamada H, Gohyama N, Honda S, Hara T, Harada N, Oguri K. Estrogen-dependent regulation of the expression of hepatic Cyp2b and 3a isoforms: assessment using aromatase-deficient mice. Toxicol Appl Pharmacol 2002;180:1-10.
28. Masubuchi Y, Iwasa T, Hosokawa S, Suzuki T, Horie T, Imaoka S, et al. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J Pharmacol Exp Ther 1997;282:1435-1441.
29. Matsumura T, Ito A, Takii T, Hayashi H, Onozaki K. Endotoxin and cytokine regulation of toll-like receptor (TLR) 2 and TLR4 gene expression in murine liver and hepatocytes. J Interferon Cytokine Res 2000;20:915-921.
30. Liu S, Gallo DJ, Green AM, Williams DL, Gong X, Shapiro RA, et al. Role of toll-like receptors in changes in gene expression and NF-kappa B activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect Immun 2002;70:3433-3442.
31. Shedlofsky SI, Swim AT, Robinson JM, Gallicchio VS, Cohen DA, McClain CJ. Interleukin-1 (IL-1) depresses cytochrome P450 levels and activities in mice. Life Sci 1987;40:2331-2336.
32. Liu J, Sendelbach LE, Parkinson A, Klaassen CD. Endotoxin pretreatment protects against the hepatotoxicity of acetaminophen and carbon tetrachloride: role of cytochrome P450 suppression. Toxicology 2000;147:167-176.
33. Williams JF, Lowitt S, Szentivanyi A. Endotoxin depression of hepatic mixed function oxidase system in C3H/HeJ and C3H/HeN mice. Immunopharmacology 1980;2:285-291.
34. Shedlofsky SI, Tosheva RT, Snawder JA. Depression of constitutive murine cytochromes P450 by staphylococcal enterotoxin B. Biochem Pharmacol 2000;59:1295-1303.
35. Ghezzi P, Saccardo B, Bianchi M. Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice. Biochem Biophys Res Commun 1986;136:316-321.
36. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is intefieukin 6 dependent. Hepatology 2000;32:49-55.
37. Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA. Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther 1999;288:945-950.
38. Warren GW, van Ess PJ, Watson AM, Mattson MP, Blouin RA. Cytochrome P450 and antioxidant activity in interleukin-6 knockout mice after induction of the acute-phase response. J Interferon Cytokine Res 2001;21:821-826.
39. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 2000;164:966-972.
40. Fleming S, Toratani S, Shea-Donohue T, Kashiwabara Y, Vogel SN, Metcalf ES. Pro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol. Alcohol Clin Exp Res 2001;25:579-589.
41. Hausmann M, Kiessling S, Mestermann S, Webb G, Spottl T, Andus T, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002;122:1987-2000.
42. Beck PL, Xavier R, Lu N, Nanda NN, Dinauer M, Podolsky DK, et al. Mechanisms of NSAID-induced gastrointestinal injury defined using mutant mice. Gastroenterology 2000;119:699-705.
43. Rachmilewitz D, Simon PL, Schwartz LW, Griswold DE, Fondacaro JD, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989;97:326-337.
44. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 2001;98:13249-13254.
45. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002;109:883-893.
46. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-451.